The company has not filed an annual or quarterly report since its Q3 FY2020 10-Q, filed Nov 13, 2020. Its latest SEC filing is a SC 13G/A from Feb 16, 2021.
10-Q for Q3 FY2020, filed Nov 13, 2020
The sections below describe the company as of the FY2019 annual report.
Develops AAV-based gene therapies for patients with genetically defined neurodegenerative diseases, including Parkinson’s disease, Gaucher disease and frontotemporal dementia.
10-K for FY2019, filed Mar 26, 2020
No revenue was reported.
10-K for FY2019, filed Mar 26, 2020
10-Q for Q3 FY2020, filed Nov 13, 2020
−$18.6MView ↗
8-K, filed Jan 22, 2021
As previously disclosed in the Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) by Prevail…View ↗
Competes with Sanofi Genzyme, Lysosomal Therapeutics, Alector, Passage Bio, Alkermes, Arkuda Therapeutics, AbbVie, BlueRock Therapeutics, Biogen, Denali Therapeutics, Prothena, Roche Holding, and Voyager Therapeutics
10-K for FY2019, filed Mar 26, 2020We consider our most direct competitors with respect to PR001 to be companies developing GCase pathway-targeting therapies, including…View ↗
Loading...
